Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

IMPACT Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment

Coordinator
Universita Degli Studi Di Padova, Italy
Runs
1 October 2023 to 30 September 2027
Status
Running
EU funding
€4.2m
Total cost
€4.2m
Partners
8 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101115536

What the project is doing

In the project's own words, from its summary on CORDIS.

Arrhythmogenic cardiomyopathy (ACM) is a genetic disease characterized by progressive cardiomyocyte loss and fibrofatty replacement, which in turn lead to the occurrence of ventricular arrhythmias and sudden cardiac death (SCD), particularly in the young and athletes. At present, ACM is uncurable; with an incidence of 1:5000, it can be considered a major CVD disease. The subform involving only the right ventricle is the most common; the majority of its causative mutations are identified in just three desmosomal genes: PKP2, DSP, and DSG2.

However, many of the identified variants in these disease genes are still of uncertain clinical significance (VUS) and thus of limited clinical utility. The overall aim of the project is to combine large-scale data from genomics, proteomics and instrumental analysis obtained from patients with data from structural and functional analyses of in vitro (3D microtissue) and in vivo (murine) models, to establish the genotype/cardiac phenotype relationship, potentially leading to a better understanding of the role and impact of known genes and epigenetic factors (ie, miRNAs) on susceptibility, clinical progression, and treatment of ACM.The project’s outcomes will pave the way towards novel therapies for ACM.

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di PadovaPadovaItalyCoordinator
KsilinkStrasbourgFranceParticipant
Consorzio ItalbiotecMilanoItalyParticipant
Italfarmaco SpAMilanoItalyParticipant
Lutech SpAMilanoItalyParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Associação AccelbioCantanhedePortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI